Crossmark

Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reporting system for anticancer drug-associated interstitial lung disease

Crossref DOI link: https://doi.org/10.1007/s00210-026-05016-2

Published Online: 2026-01-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Shun

Miao, Weijian

Tao, Qimeng

Sun, Jingjing

Huang, Zhifei

Zhou, Yan

Jiang, Hao
Funding

Funding for this research was provided by:

the Research Funds of Joint Research Center for Regional Diseases of IHM (2023bydjk003)

Anhui Provincial Key R&D Programmes (202304295107020078)
License Information

Text and Data Mining valid from 2026-01-29

Version of Record valid from 2026-01-29
More Information

Article History

Received: 15 October 2025

Accepted: 14 January 2026

First Online: 29 January 2026

Declarations

:

: This study analyzed publicly available, de-identified data and was therefore exempt from review by the Institutional Review Board of The First Affiliated Hospital of Bengbu Medical University. The research was conducted in accordance with the Declaration of Helsinki.

: Not applicable.

: Not applicable.

: The authors declare no competing interests

Document is current

Any future updates will be listed below